US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
David R. Bailey, President and CEO of OrthoPediatrics Corp. (NASDAQ:KIDS), a $614 million market cap company trading near InvestingPro’s Fair Value estimate, recently sold shares of the company, according to a Form 4 filing with the Securities and Exchange Commission. The company has shown strong revenue growth of 38% over the last twelve months. On March 18, Bailey sold 6,620 shares at a price of $24.86 each, amounting to a total transaction value of $164,573. This sale was conducted to satisfy tax withholding obligations upon the vesting of restricted shares.
Following this transaction, Bailey holds 319,155 shares of OrthoPediatrics, which includes restricted stock awards totaling 232,335 shares. The sale reflects a small portion of his overall holdings in the company.
In other recent news, OrthoPediatrics Corporation reported a significant miss in its fourth-quarter 2024 earnings per share (EPS), posting a loss of $0.69 compared to the forecasted loss of $0.30. Despite this, the company’s revenue exceeded expectations, reaching $52.7 million against the anticipated $50.72 million, marking a 40% year-over-year increase. Analysts from Stifel have adjusted their price target for OrthoPediatrics, reducing it from $40.00 to $32.00, while maintaining a Buy rating. The company aims for a 15-18% revenue growth in 2025 and anticipates its first positive free cash flow by the fourth quarter of that year.
Management has highlighted several key growth drivers, including the expansion of the Specialty Bracing franchise and the introduction of new products like the PNP Tibia and DF2 Fracture Brace. The company’s U.S. revenue saw a substantial 52% increase year-over-year, contributing to its strong overall performance. OrthoPediatrics is also focusing on international growth, particularly in Europe, with anticipated regulatory approvals that could further boost its market presence. Analyst Rick Wise (LON:WISEa) from Stifel expressed optimism about the company’s future, citing potential market share gains and a promising product portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.